Navigation Links
Cytopia To Present Data on FMS Program With Anticancer Potential
Date:6/17/2008

MELBOURNE, Australia, June 18 /PRNewswire/ -- Cytopia Limited (ASX: CYT) will present details of its FMS drug discovery and development program at the Protein Kinase Targets conference, a leading conference for breakthrough scientific data on new kinase inhibitory drugs. This conference will be held from 23 to 25 June in Boston, USA.

This is the first scientific disclosure of data from the Cytopia FMS program and will be presented by Cytopia Senior Scientist Dr Michael Harte. Dr Harte's presentation is scheduled for 3:15 pm (US EDT) 25 June.

The presentation will describe the potent activity of a series of compounds discovered at Cytopia. These compounds inhibit the function of macrophages, key cells in the immune system and mediators of inflammatory reactions. As such these compounds have therapeutic potential in treating conditions such as rheumatoid arthritis. The inhibition of cells that are responsible for bone osteolysis in advanced cancer disease is also part of the physiological potential of FMS inhibitors.

Preliminary data on the potential of Cytopia's potent FMS inhibitors to treat advanced cancer in in vivo models will also be presented at this conference.

Cytopia CEO Mr Andrew Macdonald said, "We are very encouraged by the excellent preclinical profile of these compounds. This first public disclosure of our work raises the profile of this program to the broader scientific community and reflects the excellent science undertaken by the team."

This presentation is in the same month that Cytopia presented its CYT997 cancer findings to ASCO, the world's biggest oncology conference held in Chicago.

About Cytopia

Cytopia Ltd is an Australian biotechnology company focused on the discovery and development of new drugs to treat cancer and other diseases. Cytopia conducts its research and development via subsidiaries based in Melbourne, Australia and New York and specializes in discovering new molecules with an improved therapeutic profile for the treatment of cancer. Cytopia's lead compound, CYT997, is currently in Phase II clinical trials.

Website: http://www.cytopia.com.au


'/>"/>
SOURCE Cytopia Limited
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cytopia Commences Phase II Cancer Drug Study
2. Gentiva(R) Health Services to Present June 24 at Jefferies 2nd Annual Healthcare Conference in New York
3. Parks Associates Analysts Present Insights on Broadband, Digital Content, Advertising, Home Systems, and Digital Health at CONNECTIONS(TM)
4. Emageon to Present at the Jefferies 2nd Annual Healthcare Conference
5. Bioniche Presents E. coli O157:H7 Vaccine Data to International Congress of Medical Microbiology in Serbia
6. VNUS Medical Technologies to Present at William Blair & Companys 28th Annual Growth Stock Conference
7. WebMD to Present at the William Blair 28th Annual Growth Stock Conference
8. Cardiva Medical, Inc. to Present at the Investment In Innovation (In3) Medical Device Summit on June 18, 2008 in San Francisco, CA; Announces the Completion of Its Latest Phase in Its US Sales Force Expansion
9. Digirad Corporation to Present at CapStone Small-Cap Investor Conference
10. Haemacure to Present at the BioInternational Convention - The Global Event for Biotechnology - at the San Diego Convention Centre, California, from June 17 - 20, 2008
11. EntreMed to Present at the BIO 2008 Annual International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro Health ... partnership to prep patients for colonoscopy at the HyGIeaCare® Center that is to ... Miami, FL. , The HyGIeaCare® Prep, cleared by the U.S. Food ...
(Date:3/24/2017)... ... 2017 , ... “Finding Christ Through Social Media: Year One ... the writer’s path toward true communion with God. “Finding Christ Through Social Media: ... creation of published author Lea Michelle Johnson, a follower of Christ, wife and ...
(Date:3/24/2017)... ... March 24, 2017 , ... “The Communion of ... people of God in congregations across the United States. “The Communion of ... in 1964 who has served congregations in seven states throughout his long career ...
(Date:3/23/2017)... ... 23, 2017 , ... A recent report from the National Council on Teacher ... NCTQ report suggests, based on a review of GPA and SAT/ACT requirements at 221 ... the U.S. It argues that this higher bar should be set by states, by ...
(Date:3/23/2017)... ... March 23, 2017 , ... Texas Physical Therapy Specialists (TexPTS) ... Road in Building 2. The clinic is the group’s second in New Braunfels and ... the company’s second New Braunfels location brings things full circle for the group, “It’s ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The report provides separate comprehensive analytics for the US, Canada ... Asia-Pacific , Latin America , and ... 2015 through 2022. Also, a six-year historic analysis is provided for these ...
(Date:3/24/2017)... , March 24, 2017  Eli Lilly ... announced plans to invest $850 million in its ... facilities across its U.S. enterprise, including research laboratories, ... investments are being driven by demand for Lilly ... potential medicines in development targeting cancer, pain, diabetes ...
(Date:3/24/2017)... , March 23, 2017  Mirabilis Medical, ... advanced medical technology for non-invasive surgery, announced today ... System for treatment of uterine fibroids throughout the ... had received approval from the US Food and ... the Mirabilis System in the United States.  The ...
Breaking Medicine Technology: